3D cell-laden polymers to release bioactive products in the eye

Gorka Orive; Edorta Santos-Vizcaino; Jose Luis Pedraz; Rosa Maria Hernandez; Julia E Vela Ramirez; Alireza Dolatshahi-Pirouz; Ali Khademhosseini; Nicholas A Peppas; Dwaine F Emerich

doi:10.1016/j.preteyeres.2018.10.002

3D cell-laden polymers to release bioactive products in the eye

Prog Retin Eye Res. 2019 Jan:68:67-82. doi: 10.1016/j.preteyeres.2018.10.002. Epub 2018 Oct 18.

Authors

Gorka Orive¹, Edorta Santos-Vizcaino², Jose Luis Pedraz², Rosa Maria Hernandez², Julia E Vela Ramirez³, Alireza Dolatshahi-Pirouz⁴, Ali Khademhosseini⁵, Nicholas A Peppas⁶, Dwaine F Emerich⁷

Affiliations

¹ NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country UPV/EHU, Paseo de la Universidad 7, 01006, Vitoria-Gasteiz, Spain; Biomedical Research Networking Centre in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain; University Institute for Regenerative Medicine and Oral Implantology - UIRMI (UPV/EHU-Fundación Eduardo Anitua), Vitoria, Spain; Singapore Eye Research Institute, The Academia, 20 College Road, Discovery Tower, Singapore. Electronic address: gorka.orive@ehu.eus.
² NanoBioCel Group, Laboratory of Pharmaceutics, School of Pharmacy, University of the Basque Country UPV/EHU, Paseo de la Universidad 7, 01006, Vitoria-Gasteiz, Spain; Biomedical Research Networking Centre in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Vitoria-Gasteiz, Spain.
³ Department of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA; Institute for Biomaterials, Drug Delivery, and Regenerative Medicine, The University of Texas at Austin, Austin, TX, USA.
⁴ Department of Micro- and Nanotechnology, Center for Nanomedicine and Theranostics, Technical University of Denmark, Kgs. Lyngby, 2800, Denmark.
⁵ Department of Bioengineering, Department of Chemical and Biomolecular Engineering, Henry Samueli School of Engineering and Applied Sciences, University of California-Los Angeles, Los Angeles, CA, USA; Center for Minimally Invasive Therapeutics (C-MIT), University of California-Los Angeles, Los Angeles, CA, USA; California NanoSystems Institute (CNSI), University of California-Los Angeles, Los Angeles, CA, USA; Department of Radiology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.
⁶ Department of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA; Institute for Biomaterials, Drug Delivery, and Regenerative Medicine, The University of Texas at Austin, Austin, TX, USA; McKetta Department of Chemical Engineering, The University of Texas at Austin, Austin, TX, USA; Division of Pharmaceutics, College of Pharmacy, The University of Texas at Austin, Austin, TX, USA.
⁷ Gloriana Therapeutics, Inc, 225 Chapman St., Providence, RI, USA. Electronic address: DFE@GlorianaTx.com.

PMID: 30342088
DOI: 10.1016/j.preteyeres.2018.10.002

Abstract

Millions of people worldwide suffer from debilitating, progressive, and often permanent loss of vision without any viable treatment options. The complex physiological barriers of the eye contribute to the difficulty in developing novel therapies by limiting our ability to deliver therapeutics in a sustained and controlled manner; especially when attempting to deliver drugs to the posterior eye or trying to regenerate the diseased retina. Cell-based therapies offer a significant potential advancement in these situations. In particular, encapsulating, or immunoisolating, cells within implantable, semi-permeable membranes has emerged as a clinically viable means of delivering therapeutic molecules to the eye for indefinite periods of time. The optimization of encapsulation device designs is occurring together with refinements in biomaterials, genetic engineering, and stem-cell production, yielding, for the first time, the possibility of widespread therapeutic use of this technology. Here, we highlight the status of the most advanced and widely explored iteration of cell encapsulation with an eye toward translating the potential of this technological approach to the medical reality.

Keywords: Cell therapy; Drug delivery; Encapsulated cell technology; Encapsulation; Ophthalmic diseases; Protein.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Biological Products / administration & dosage*
Cell- and Tissue-Based Therapy / methods*
Drug Delivery Systems*
Eye Diseases / therapy*
Humans
Polymers / administration & dosage*

Substances

Biological Products
Polymers